Identification
NameOxymetholone
Accession NumberDB06412
TypeSmall Molecule
GroupsApproved, Illicit
Description

Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limited. Its primary clinical applications include treatment of osteoporosis and anaemia, as well as stimulating muscle growth in malnourished or underdeveloped patients. Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes. The uncontrolled misuse of oxymetholone can lead to a large variety of detrimental effects, the most often reported of which are cardiovascular events. In 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009).

Structure
Thumb
Synonyms
17β-Hydroxy-2-hydroxymethylidene-17α-methyl-3-androstanone
Oximetolona
Oxymetholon
Oxymétholone
Oxymetholonum
External IDs CI 406 / CI-406
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Anadrol-50Tablet50 mg/1OralAlaven Pharmaceutical1972-06-01Not applicableUs
Anapolon 50Tablet50 mgOralSyntex Inc.1970-12-311997-08-26Canada
Anapolon 50 Tablets 50mgTablet50 mgOralHoffmann La Roche1997-07-291999-03-17Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnapolonAbdi Ibrahim
AndrolicBritish Dispensary
HemogeninSanofi Aventis
Brand mixturesNot Available
Categories
UNIIL76T0ZCA8K
CAS number434-07-1
WeightAverage: 332.484
Monoisotopic: 332.23514489
Chemical FormulaC21H32O3
InChI KeyICMWWNHDUZJFDW-DHODBPELSA-N
InChI
InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1
IUPAC Name
(1S,2S,4Z,7S,10R,11S,14S,15S)-14-hydroxy-4-(hydroxymethylidene)-2,14,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-one
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O
Pharmacology
Indication

Indicated in the treatment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Oxymetholone should not replace other supportive measures such as transfusion, correction of iron, folic acid, vitamin B12 or pyridoxine deficiency, antibacterial therapy and the appropriate use of corticosteroids.

Structured Indications
PharmacodynamicsNot Available
Mechanism of action

Oxymethalone is a 17 alpha-alkylated anabolic-androgenic steroid and a synthetic derivative of testosterone, whose anabolic effects are used to treat muscle wasting in HIV patients. The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.

TargetKindPharmacological actionActionsOrganismUniProt ID
Androgen receptorProteinyes
agonist
activator
HumanP10275 details
Natriuretic peptides BProteinunknownNot AvailableHumanP16860 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
Toxicity

May cause cancer. The uncontrolled misuse of oxymetholone can lead to a large variety of detrimental effects, the most often reported of which are cardiovascular events.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the fluid retaining activities of Oxymetholone.Investigational
19-norandrostenedione19-norandrostenedione may increase the fluid retaining activities of Oxymetholone.Experimental, Illicit
5-androstenedione5-androstenedione may increase the fluid retaining activities of Oxymetholone.Experimental, Illicit
AcarboseOxymetholone may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolOxymetholone may increase the anticoagulant activities of Acenocoumarol.Approved
AlbiglutideOxymetholone may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneAlclometasone may increase the fluid retaining activities of Oxymetholone.Approved
AldosteroneAldosterone may increase the fluid retaining activities of Oxymetholone.Experimental
AlogliptinOxymetholone may increase the hypoglycemic activities of Alogliptin.Approved
AmcinonideAmcinonide may increase the fluid retaining activities of Oxymetholone.Approved
Androstenedione4-Androstenedione may increase the fluid retaining activities of Oxymetholone.Experimental, Illicit
AnecortaveAnecortave may increase the fluid retaining activities of Oxymetholone.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the fluid retaining activities of Oxymetholone.Approved, Investigational
BetamethasoneBetamethasone may increase the fluid retaining activities of Oxymetholone.Approved, Vet Approved
BromocriptineOxymetholone may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BudesonideBudesonide may increase the fluid retaining activities of Oxymetholone.Approved
CanagliflozinOxymetholone may increase the hypoglycemic activities of Canagliflozin.Approved
ChlorpropamideOxymetholone may increase the hypoglycemic activities of Chlorpropamide.Approved
CiclesonideCiclesonide may increase the fluid retaining activities of Oxymetholone.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Oxymetholone.Approved
ClobetasolClobetasol may increase the fluid retaining activities of Oxymetholone.Investigational
Clobetasol propionateClobetasol propionate may increase the fluid retaining activities of Oxymetholone.Approved
ClocortoloneClocortolone may increase the fluid retaining activities of Oxymetholone.Approved
Conestat alfaOxymetholone may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).Approved
Cortisone acetateCortisone acetate may increase the fluid retaining activities of Oxymetholone.Approved
CyclosporineOxymetholone may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
DapagliflozinOxymetholone may increase the hypoglycemic activities of Dapagliflozin.Approved
DesoximetasoneDesoximetasone may increase the fluid retaining activities of Oxymetholone.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the fluid retaining activities of Oxymetholone.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the fluid retaining activities of Oxymetholone.Approved, Investigational, Vet Approved
DicoumarolOxymetholone may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneDiflorasone may increase the fluid retaining activities of Oxymetholone.Approved
DifluocortoloneDifluocortolone may increase the fluid retaining activities of Oxymetholone.Approved
DifluprednateDifluprednate may increase the fluid retaining activities of Oxymetholone.Approved
DisopyramideOxymetholone may increase the hypoglycemic activities of Disopyramide.Approved
DulaglutideOxymetholone may increase the hypoglycemic activities of Dulaglutide.Approved
EmpagliflozinOxymetholone may increase the hypoglycemic activities of Empagliflozin.Approved
EquileninEquilenin may increase the fluid retaining activities of Oxymetholone.Experimental
EquilinEquilin may increase the fluid retaining activities of Oxymetholone.Approved
EstroneEstrone may increase the fluid retaining activities of Oxymetholone.Approved
Estrone sulfateEstrone sulfate may increase the fluid retaining activities of Oxymetholone.Approved
Ethyl biscoumacetateOxymetholone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideOxymetholone may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxymetholone.Approved
FludrocortisoneFludrocortisone may increase the fluid retaining activities of Oxymetholone.Approved
FluindioneOxymetholone may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneFlumethasone may increase the fluid retaining activities of Oxymetholone.Approved, Vet Approved
FlunisolideFlunisolide may increase the fluid retaining activities of Oxymetholone.Approved, Investigational
Fluocinolone AcetonideFluocinolone Acetonide may increase the fluid retaining activities of Oxymetholone.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the fluid retaining activities of Oxymetholone.Approved, Investigational
FluocortoloneFluocortolone may increase the fluid retaining activities of Oxymetholone.Approved, Withdrawn
FluorometholoneFluorometholone may increase the fluid retaining activities of Oxymetholone.Approved
FluprednideneFluprednidene may increase the fluid retaining activities of Oxymetholone.Approved, Withdrawn
FlurandrenolideFlurandrenolide may increase the fluid retaining activities of Oxymetholone.Approved
Fluticasone furoateFluticasone furoate may increase the fluid retaining activities of Oxymetholone.Approved
Fluticasone propionateFluticasone Propionate may increase the fluid retaining activities of Oxymetholone.Approved
FormestaneFormestane may increase the fluid retaining activities of Oxymetholone.Approved, Investigational, Withdrawn
GliclazideOxymetholone may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideOxymetholone may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideOxymetholone may increase the hypoglycemic activities of Glipizide.Approved
GlyburideOxymetholone may increase the hypoglycemic activities of Glyburide.Approved
HE3286HE3286 may increase the fluid retaining activities of Oxymetholone.Investigational
Human C1-esterase inhibitorOxymetholone may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).Approved
HydrocortisoneHydrocortisone may increase the fluid retaining activities of Oxymetholone.Approved, Vet Approved
Insulin AspartOxymetholone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirOxymetholone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineOxymetholone may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineOxymetholone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanOxymetholone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproOxymetholone may increase the hypoglycemic activities of Insulin Lispro.Approved
LanreotideOxymetholone may increase the hypoglycemic activities of Lanreotide.Approved
LiraglutideOxymetholone may increase the hypoglycemic activities of Liraglutide.Approved
ME-609ME-609 may increase the fluid retaining activities of Oxymetholone.Investigational
MecaserminOxymetholone may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneMedrysone may increase the fluid retaining activities of Oxymetholone.Approved
MetforminOxymetholone may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneMethylprednisolone may increase the fluid retaining activities of Oxymetholone.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Oxymetholone.Approved, Investigational
MifepristoneOxymetholone may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolOxymetholone may increase the hypoglycemic activities of Miglitol.Approved
MometasoneMometasone may increase the fluid retaining activities of Oxymetholone.Approved, Vet Approved
NateglinideOxymetholone may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022NCX 1022 may increase the fluid retaining activities of Oxymetholone.Investigational
OctreotideOxymetholone may increase the hypoglycemic activities of Octreotide.Approved, Investigational
Oleoyl-estroneOleoyl estrone may increase the fluid retaining activities of Oxymetholone.Investigational
ParamethasoneParamethasone may increase the fluid retaining activities of Oxymetholone.Approved
PasireotideOxymetholone may increase the hypoglycemic activities of Pasireotide.Approved
PentamidineOxymetholone may increase the hypoglycemic activities of Pentamidine.Approved
PhenindioneOxymetholone may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonOxymetholone may increase the anticoagulant activities of Phenprocoumon.Approved
PioglitazoneOxymetholone may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PramlintideOxymetholone may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteronePrasterone may increase the fluid retaining activities of Oxymetholone.Approved, Nutraceutical
Prasterone sulfatedehydroepiandrosterone sulfate may increase the fluid retaining activities of Oxymetholone.Investigational
PrednicarbatePrednicarbate may increase the fluid retaining activities of Oxymetholone.Approved
PrednisolonePrednisolone may increase the fluid retaining activities of Oxymetholone.Approved, Vet Approved
PrednisonePrednisone may increase the fluid retaining activities of Oxymetholone.Approved, Vet Approved
PregnenolonePregnenolone may increase the fluid retaining activities of Oxymetholone.Experimental
QuinineOxymetholone may increase the hypoglycemic activities of Quinine.Approved
RepaglinideOxymetholone may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RimexoloneRimexolone may increase the fluid retaining activities of Oxymetholone.Approved
RosiglitazoneOxymetholone may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SaxagliptinOxymetholone may increase the hypoglycemic activities of Saxagliptin.Approved
SitagliptinOxymetholone may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SulfadiazineOxymetholone may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleOxymetholone may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleOxymetholone may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibOxymetholone may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Oxymetholone.Withdrawn
TixocortolTixocortol may increase the fluid retaining activities of Oxymetholone.Approved
TolazamideOxymetholone may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideOxymetholone may increase the hypoglycemic activities of Tolbutamide.Approved
TriamcinoloneTriamcinolone may increase the fluid retaining activities of Oxymetholone.Approved, Vet Approved
WarfarinOxymetholone may increase the anticoagulant activities of Warfarin.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Pavlatos AM, Fultz O, Monberg MJ, Vootkur A, Pharmd: Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther. 2001 Jun;23(6):789-801; discussion 771. [PubMed:11440282 ]
  2. Authors unspecified: Oxymetholone. Rep Carcinog. 2011;12:338-40. [PubMed:21860526 ]
  3. Vergel N: Building your body to survive: the use of anabolic steroids for HIV therapy. Posit Aware. 1998 Mar-Apr;9(2):37-41. [PubMed:11365225 ]
  4. Davison SL, Bell R: Androgen physiology. Semin Reprod Med. 2006 Apr;24(2):71-7. [PubMed:16633980 ]
  5. Report on Carcinogens, Thirteenth Edition [Link]
External Links
ATC CodesA14AA05 — Oxymetholone
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (172 KB)
MSDSDownload (490 KB)
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral50 mg/1
TabletOral50 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)178°C to 180°CReport on Carcinogens, Thirteenth Edition
water solubility5.21 mg/LReport on Carcinogens, Thirteenth Edition
Predicted Properties
PropertyValueSource
Water Solubility0.0349 mg/mLALOGPS
logP3.17ALOGPS
logP3.55ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)8.87ChemAxon
pKa (Strongest Basic)-0.53ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity94.6 m3·mol-1ChemAxon
Polarizability38.84 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassAndrostane steroids
Direct ParentAndrogens and derivatives
Alternative Parents3-oxo-5-alpha-steroids / 17-hydroxysteroids / Vinylogous acids / Tertiary alcohols / Cyclic ketones / Cyclic alcohols and derivatives / Enols / Organic oxides / Hydrocarbon derivatives
SubstituentsAndrogen-skeleton / 3-oxosteroid / 3-oxo-5-alpha-steroid / 17-hydroxysteroid / Oxosteroid / Hydroxysteroid / Cyclic alcohol / Vinylogous acid / Tertiary alcohol / Cyclic ketone
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsAndrostane and derivatives (C07393 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonistactivator
General Function:
Zinc ion binding
Specific Function:
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Gene Name:
AR
Uniprot ID:
P10275
Uniprot Name:
Androgen receptor
Molecular Weight:
98987.9 Da
References
  1. Davison SL, Bell R: Androgen physiology. Semin Reprod Med. 2006 Apr;24(2):71-7. [PubMed:16633980 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor binding
Specific Function:
Cardiac hormone which may function as a paracrine antifibrotic factor in the heart. Also plays a key role in cardiovascular homeostasis through natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. Specifically binds and stimulates the cGMP production of the NPR1 receptor. Binds the clearance receptor NPR3.
Gene Name:
NPPB
Uniprot ID:
P16860
Uniprot Name:
Natriuretic peptides B
Molecular Weight:
14725.825 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Uniprot Name:
Amine oxidase [flavin-containing] A
Molecular Weight:
59681.27 Da
References
  1. Thiblin I, Finn A, Ross SB, Stenfors C: Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids. Br J Pharmacol. 1999 Mar;126(6):1301-6. [PubMed:10217522 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
References
  1. Pavlatos AM, Fultz O, Monberg MJ, Vootkur A, Pharmd: Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther. 2001 Jun;23(6):789-801; discussion 771. [PubMed:11440282 ]
3. Cytochrome p450 3A subfamily
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
References
  1. Pavlatos AM, Fultz O, Monberg MJ, Vootkur A, Pharmd: Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther. 2001 Jun;23(6):789-801; discussion 771. [PubMed:11440282 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Uniprot Name:
Cytochrome P450 1A2
Molecular Weight:
58293.76 Da
References
  1. Pavlatos AM, Fultz O, Monberg MJ, Vootkur A, Pharmd: Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther. 2001 Jun;23(6):789-801; discussion 771. [PubMed:11440282 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Uniprot Name:
Cytochrome P450 2C19
Molecular Weight:
55930.545 Da
References
  1. Pavlatos AM, Fultz O, Monberg MJ, Vootkur A, Pharmd: Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther. 2001 Jun;23(6):789-801; discussion 771. [PubMed:11440282 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
substrateactivator
General Function:
Electron carrier activity
Specific Function:
Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
Gene Name:
SRD5A1
Uniprot ID:
P18405
Uniprot Name:
3-oxo-5-alpha-steroid 4-dehydrogenase 1
Molecular Weight:
29458.18 Da
References
  1. Pavlatos AM, Fultz O, Monberg MJ, Vootkur A, Pharmd: Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther. 2001 Jun;23(6):789-801; discussion 771. [PubMed:11440282 ]
  2. Davison SL, Bell R: Androgen physiology. Semin Reprod Med. 2006 Apr;24(2):71-7. [PubMed:16633980 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Uniprot Name:
Serum albumin
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Androgen binding
Specific Function:
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.
Gene Name:
SHBG
Uniprot ID:
P04278
Uniprot Name:
Sex hormone-binding globulin
Molecular Weight:
43778.755 Da
Drug created on March 19, 2008 10:31 / Updated on August 02, 2017 17:09